Although these studies engineered EVs for targeting HER2 overexpressing breast cancer cells, this technology could be modified to other targeting ligands to create EVs for delivering mRNA to any disease that is characterized by the overexpression of receptors such as PSMA (prostate cancer), bombasin (gastric cancer), folate (epithelial cancer), and transferrin (breast cancer). The gene discussed is FOLH1; the disease is breast cancer.